New clinical trials presented at the American Diabetes Association's Scientific Sessions show that survodutide has promising results for reducing HbA1c levels and improving insulin sensitivity, with additional favorable changes in glucose-related biomarkers.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
New research presented at the American Diabetes Association Scientific Sessions in Orlando, Florida, reveals the significant efficacy of ecnoglutide (XW003), a novel cAMP signaling biased GLP-1 analog, in adults with type 2 diabetes mellitus and obesity in China.